KRAS Mutation Test v2 (LSR)

The KRAS Mutation Test v2 (LSR) from Roche is an allele-specific, real-time PCR test for the qualitative detection and identification of exon 2, 3, and 4 mutations in the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene from formalin-fixed, paraffin-embedded tissue (FFPET) or plasma samples.

KEY FEATURES AND BENEFITS

- Broad coverage of 28 KRAS mutations within an 8-hour laboratory shift
- Validated in FFPET samples and can reliably detect KRAS variants at ≥1 % mutation from a single, 5µm section.
- Validated in plasma samples with sensitivity of 75 copies /mL or lower in a wild-type background of 64,000 copies from just 2mL of plasma.
- Can be paired with the BRAF/NRAS Mutation Test (LSR) for broad detection of 64 unique RAS/BRAF variants in a single PCR run
- A web-based analysis tool enables automated, objective, and rapid interpretation of results
KRAS v2 LSR* TESTING WORKFLOW

When you’re on the path to discovery, every result matters. Every answer could be the one that gets you there. To the revelation you were searching for. To the advancement you needed. To your next breakthrough. The Roche Life Science Research Oncology Portfolio offers the speed, accuracy, and open-source flexibility your research demands. So you get clear, actionable results faster, in fewer shifts, and backed by the exacting standards, quality, and service of Roche.

COVERAGE OF THE KRAS MUTATION TEST v2 (LSR*)

<table>
<thead>
<tr>
<th>KRAS COSMIC† v81</th>
<th>COLON</th>
<th>Freq of Reports</th>
<th>LSR* Coverage</th>
<th>LUNG</th>
<th>Freq of Reports</th>
<th>LSR* Coverage</th>
<th>PANCREAS</th>
<th>Freq of Reports</th>
<th>LSR* Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>exon 2</td>
<td>98.3%</td>
<td>97.7%</td>
<td></td>
<td>exon 2</td>
<td>98.7%</td>
<td>97.7%</td>
<td>exon 2</td>
<td>98.8%</td>
<td>98.3%</td>
</tr>
<tr>
<td>exon 3</td>
<td>1.0%</td>
<td>0.9%</td>
<td></td>
<td>exon 3</td>
<td>1.2%</td>
<td>1.1%</td>
<td>exon 3</td>
<td>1.1%</td>
<td>1.0%</td>
</tr>
<tr>
<td>exon 4</td>
<td>0.7%</td>
<td>0.5%</td>
<td></td>
<td>exon 4</td>
<td>0.06%</td>
<td>0.04%</td>
<td>exon 4</td>
<td>0.08%</td>
<td>0.04%</td>
</tr>
<tr>
<td>all others**</td>
<td>0.01%</td>
<td>0.0%</td>
<td></td>
<td>all others**</td>
<td>0.04%</td>
<td>0.0%</td>
<td>all others**</td>
<td>0.0%</td>
<td>0.0%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>100%</td>
<td>99.1%</td>
<td></td>
<td>TOTAL</td>
<td>100%</td>
<td>98.8%</td>
<td>TOTAL</td>
<td>100%</td>
<td>99.3%</td>
</tr>
</tbody>
</table>

numbers are rounded to the nearest decimal point
† Catalog of Somatic Mutations in Cancer
**mutations outside exons 2, 3, and 4

*FOR LIFE SCIENCE RESEARCH ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

FOR MORE INFORMATION
Contact your local Roche Molecular Diagnostic representative or visit oncologyresearchkits.roche.com.